Autoantibodies in patients with psoriatic arthritis on anti-TNFα therapy

Revista Brasileira de Reumatologia

Volumn 50, Issue 3, 2010, Pages 230-234

  Trindade Viana, Vilma S ^a   de Carvalho, Jozélio Freire ^b   de Moraes, Júlio César Bertacini ^b   Saad, Carla Gonçalves Schain ^b   Ribeiro, Ana Cristina de Medeiros ^b   Gonçalves, Célio ^b   Bueno, Cleonice ^a   Vendramini, Margarete B ^a   Bonfá, Eloísa ^b  

^a LIM/17 FMUSP ^*

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anti TNF ; Autoantibodies; Psoriatic arthritis; Therapy

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CARDIOLIPIN ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOSPORIN; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; ETRETIN; HISTONE ANTIBODY; INFLIXIMAB; LA ANTIBODY; LEFLUNOMIDE; METHOTREXATE; RHEUMATOID FACTOR; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SM ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DISEASE DURATION; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOFLUORESCENCE; MALE; PSORIATIC ARTHRITIS; RECOMMENDED DRUG DOSE; BLOOD; DRUG ANTAGONISM; MIDDLE AGED;

ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; AUTOANTIBODIES; FEMALE; HUMANS; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954710912     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kleinert S, Feuchtenberger M, Kneitz C, Tony HP. Psoriatic arthritis: clinical spectrum and diagnostic procedures. Clinics Dermatol 2007; 25:519-23.
2. Abdel Fattah NS, Hassan HE, Galal ZA, El Okda el SE. Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis. BMC Res Notes 2009; 2:44.
3. Shibata S, Tada Y, Komine M, Hattori N, Osame S, Kanda N et al. Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis. J Dermatol Sci 2009; 53:34-9.
4. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54:2665-73.
5. Gladman DD. Spondyloarthropathies: targeted therapy for psoriatic arthritis. Nat Rev Rheumatol 2009; 5:241-2.
6. Mease PJ. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 2002; 61:298-304.
7. Ramos-Casals M, Brito-Zerón P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008; 22:847-61.
8. De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003; 48:1015-23.
9. Garcia-Planella E, Domènech E, Esteve-Comas M, Bernal I, Cabré E, Boix J et al. Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNF alpha antibodies (infliximab). Eur J Gastroenterol Hepatol 2003;15:351-4.
10. Bacquet-Deschryver H, Jouen F, Quillard M, Ménard JF, Goëb V, Lequerré T et al. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J Clin Immunol 2008; 28:445-55.
11. Poulalhon N, Begon E, Lebbé C, Lioté F, Lahfa M, Bengoufa D et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol 2007; 156:329-36.
12. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F. The effect of TNF alpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 2005; 14:931-7.
13. Moll JM, Wright V. Psoriatic arthritis. Sem Arthritis Rheum 1973; 3:55-78.
14. Tan EM, Peebles C. Quantitation of antibodies to Sm antigen and nuclear ribonucleoprotein by hemagglutination. In: Rose NR, Friedman H (eds.). Manual of clinical immunology. 2nd ed. Washington: American Society of Microbiology, 1980, pp. 866-70.
15. Cruz RB, Viana VS, Nishioka SA, Martinelli-F M, Bonfa E. Is isolated congenital heart block associated to neonatal lupus requiring pacemaker a distinct cardiac syndrome? Pacing Clin Electrophysiol 2004; 27:615-20.
16. Allanore Y, Sellam J, Batteux F, Job Deslandre C, Weill B, Kahan A. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clin Exp Rheumatol 2004; 22:756-8.
17. Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 2004; 6:R535-43.
18. Johnson SR, Schentag CT, Gladman DD. Autoantibodies in biological agent naive patients with psoriatic arthritis. Ann Rheum Dis 2005; 64:770-2.
19. Dellavance A, Leser PG, Andrade LEC. Análise crítica do teste de anticorpos antinúcleo (FAN) na prática clínica. Rev Bras Reumatol 2007; 47:265-75.
20. Smeenk R, Brinkman K, van den Brink H, Termaat RM, Berden J, Nossent H et al. Antibodies to DNA in patients with systemic lupus erythematosus. Their role in the diagnosis, the follow-up and the pathogenesis of the disease. Clin Rheumatol 1990; 9:100-10.
21. Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004; 63:1218-21.
22. Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 2004; 6:R264-R72.